SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is experiencing extreme volatility and a sharp sell-off following its recent quarterly financial results, with the community actively debating whether the decline is an overreaction to record-breaking revenue or a necessary market correction. Many investors are currently focused on whether this drawdown presents a buying opportunity, while others remain skeptical and caution against catching a falling knife.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is attracting significant community attention as traders anticipate a pivotal regulatory decision regarding the sBLA filing for Anktiva, while monitoring recent earnings performance and international expansion efforts. The broader discussion is dominated by debates over non-cash accounting adjustments in the latest financial report and expectations for upcoming clinical data presentations.

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Atara Biotherapeutics Inc

Atara Biotherapeutics is trending as investors react to a significant regulatory update regarding a potential FDA path forward for tabelecleucel, with the community actively debating the company's financial position and the likelihood of future capital raises. Traders are highlighting intense volatility and high volume as they monitor the stock's technical performance and assess the risk-reward profile ahead of upcoming regulatory milestones.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. Its storage includes Smartstack, Gridstack Pro, Grisdtack, and Ultrastack. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

Fluence Energy is seeing significant market interest as investors weigh its record $5.6 billion backlog and growing data center hyperscaler partnerships against ongoing profitability challenges. The community is actively debating whether the recent momentum represents a genuine re-rating of the company's long-term infrastructure potential or continued execution risk.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is experiencing extreme market volatility as investors weigh strong AI-driven demand and long-term revenue potential against supply chain constraints and a stretched valuation. While the community remains deeply divided between long-term bulls betting on the company's role as the architectural backbone of AGI and skeptics warning of a speculative bubble, price action continues to be driven by aggressive rotation and institutional profit-taking following recent earnings.

TSS, Inc. engages in the provision of comprehensive services for the planning, design, development and maintenance of mission-critical facilities and information infrastructure as well as integration services. It operates through the Facilities and Systems Integration Services business segments. The Facilities segment consists of the design, project management, and maintenance of data center and mission-critical business operations. The Systems Integration segment integrates information technology equipment for original equipment manufacturer vendors and customers to be used inside data center environments, including modular data centers. The company was founded by Gerard J. Gallagher on December 20, 2004 and is headquartered in Georgetown, TX.

TSS Inc

TSSI is trending following an earnings report that showcased record-breaking revenue and profit growth, sparking intense community debate over whether the stock is undervalued or a temporary pump-and-dump. While bullish investors point to a massive AI infrastructure backlog and strategic partnerships with Dell as catalysts for a potential re-rate, skeptics are actively highlighting the lack of explicit revenue guidance and aggressive price volatility as reasons to lock in profits.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is trending due to a combination of strong institutional interest, strategic warrant exchanges aimed at reducing dilution, and a bullish growth outlook tied to its silicon anode battery technology for the drone and electric mobility sectors. The community remains focused on the company's long-term potential and operational milestones, often interpreting recent price volatility as a buying opportunity rather than a shift in fundamental strength.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending as investors react to high-stakes speculation surrounding ongoing diplomatic and military maneuvers in the Strait of Hormuz. The community is actively debating the credibility of reported peace framework negotiations versus potential escalation, with many traders closely monitoring for signs of market manipulation and insider activity around the conflict.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently the center of intense investor focus as the community anticipates strong Q1 earnings and potential updates regarding the Neutron rocket, hypersonic defense contracts, and strategic acquisitions like Mynaric. Traders are closely monitoring these developments alongside broader sector rotation, with many viewing current price fluctuations as a consolidation phase before a potential rally fueled by the company's expanding backlog and pivotal role in U.S. national security infrastructure.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending as investors weigh strong profitability and recent AAA-rated bond successes against broader geopolitical tensions and volatility in the fintech sector. While the community is actively debating the company's valuation gap compared to peers, sentiment remains divided between those expecting a potential short squeeze around upcoming earnings and skeptics focused on institutional insider selling.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Capricor Therapeutics (CAPR) Projected to Post Earnings on Tuesday

Capricor Therapeutics (NASDAQ:CAPR) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 12. (View Earnings Report at...

Oppenheimer & Co. Inc. Cuts Stock Holdings in Capricor Therapeutics, Inc. $CAPR

Oppenheimer & Co. Inc. trimmed its position in shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) by 40.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 80,813 shares of the biotechnology company's stock after selling 54,600 s...

Capricor Therapeutics (NASDAQ:CAPR) Shares Up 7.1% - Still a Buy?

Capricor Therapeutics (NASDAQ:CAPR) Trading 7.1% Higher - What's Next...

<ul class="summary-bullets"><li>Hemmati is reportedly being considered for a leadership role at the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research.</li><li>The regulatory spotlight has intensified following recent FDA moves, including the fast-tracked expanded access for Revolution Medicines’ cancer drug, Daraxonrasib.</li><li>Capricor awaits an FDA decision on Deramiocel by Aug. 22.</li></ul>Shares of Capricor Therapeutics, Inc. (CAPR) drew retail attention on Monday after a former executive, eyeing a potential FDA chief role, said drug approval should only be viewed as a “building permit” rather than a sign that a therapy is the top choice.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> declined 8% on Friday as investors tracked regulatory developments ahead of a high-stakes decision on its Duchenne muscular dystrophy (DMD) therapy, Deramiocel.The focus increased after Houman David Hemmati, who previously served at the company and is now being considered for a leadership role at the U.S. Food and Drug Administration (FDA).<h2 class="st-heading-2">Hemmati: Approval Is Just A Safety Check&nbsp;</h2>Hemmati&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/houmanhemmati/status/2051104165112303924">said on X</a> that FDA approval does not indicate that a drug is “incredible” or the best option available, but simply confirms it meets established standards for safety and efficacy. “It’s like a building permit: it simply confirms the therapy meets rigorous standards for safety and efficacy,” he said.He said that patients can choose not to take a drug, doctors may decide not to prescribe it, and insurers may opt not to cover it if it is not appropriate, stressing that approval is only one part of a broader framework for real-world use.“Taking away choice because a drug isn’t “absolutely perfect” means patients and physicians never even get the option to consider it. Putting patients first means preserving every possible tool—so families and doctors can decide together,” Hemmati said.&nbsp;<h2 class="st-heading-2">Hemmati Emerges As FDA Role Contender&nbsp;</h2>Hemmati, who served as vice president of medical and clinical development at Capricor between 2015 and 2017, is&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capr-stock-ex-capricor-exec-fda-role-ahead-of-dmd-decision/cZJpyVMRIHI">reportedly</a> among candidates being considered to lead the FDA’s Center for Biologics Evaluation and Research, which oversees gene and cell therapy approvals.The potential leadership change follows the departure of CBER director Vinay Prasad, whose tenure drew criticism from the biotech sector over decisions affecting rare-disease therapies.Recent regulatory decisions have also drawn focus to the agency’s approach. The FDA last week granted a “safe to proceed” letter to Revolution Medicines for expanded access to its pancreatic cancer drug Daraxonrasib, allowing treatment for patients with previously treated metastatic disease.The agency cleared the request within two days of submission, with Commissioner Marty Makary saying that the move is a commitment to facilitate early access to therapies for serious and life-threatening conditions. Daraxonrasib, a RAS inhibitor, has received Breakthrough Therapy and Orphan Drug designations and is expected to be submitted for approval under the agency’s National Priority Voucher program.<h2 class="st-heading-2">CAPR Awaits High-Stakes DMD Decision</h2>The developments come as Capricor awaits an FDA decision on Deramiocel, expected by Aug. 22. The therapy targets DMD, a genetic condition that causes progressive muscle weakness in children.The FDA resumed its review in March after issuing a Complete Response Letter in July 2025 requesting additional data. Capricor’s resubmission included Phase 3 Hope-3 trial results showing a 54% slowing in upper-limb function decline and a 91% reduction in cardiac disease progression compared with placebo. Deramiocel consists of donor-derived cardiac cells to reduce inflammation from muscle degeneration in DMD.<h2 class="st-heading-2">How Do Retail Traders Feel About CAPR?</h2>On Stocktwits, retail sentiment for CAPR was ‘bullish’ amid ‘normal’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/capr_ss_png_31e2b2ea6c.webp" alt="capr ss.png" width="970" height="143"><figcaption>CAPR sentiment and message volume as of May 4 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/PortfolioAutopsy/message/652143880">called</a> CAPR a “Clinical-stage biotech with high risk and potential reward tied to trial success”<stembedurl>https://stocktwits.com/PortfolioAutopsy/message/652143880</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Stonksgoingup/message/652124339">said</a>, “4 months max until we can finally start selling and get treatment for these boys. Time really flies since our end of feb submission”<stembedurl>https://stocktwits.com/Stonksgoingup/message/652124339</stembedurl>CAPR stock has surged 143% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-jumps-ev-maker-brings-back-original-software-chief/cZQMhiXRe7Z">Nio Stock Jumps Overnight: EV Maker Brings Back Original Chief To Run Software Behind Its Cars&nbsp;</a>

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CAPR Stock In Focus: Ex-Exec Eyed For FDA Role Says Drug Approvals Are Not ‘Best-In-Class’ Signals

Former Capricor executive Houman David Hemmati said FDA approval should be viewed as a “building permit,” not proof a drug is the best option.

Equity

Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.5%  - What's Next?

Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.5% - Should You Sell...

Moody Aldrich Partners LLC Takes Position in Capricor Therapeutics, Inc. $CAPR

Moody Aldrich Partners LLC purchased a new stake in Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 208,755 shares of the biotechnology compan...

<ul><li>The company’s management highlighted that video-based assessments of everyday tasks showed that Deramiocel helped slow disease progression.</li><li>The U.S. FDA is expected to announce its decision on Deramiocel on August 22.</li><li>According to a Bloomberg report, a former Capricor executive is being considered for a key leadership role at the FDA’s Center for Biologics Evaluation and Research.</li></ul>Capricor Therapeutics (CAPR) drew investor attention on Wednesday, after the biotech firm presented data from its Phase 3 HOPE-3 trial of Deramiocel for Duchenne Muscular Dystrophy (DMD) at the American Academy of Neurology 2026 Annual Meeting in Chicago.<a href="https://stocktwits.com/symbol/CAPR">CAPR shares</a> gave up early gains, trading 1% lower.<h2>FDA Decision Expected In August</h2>Capricor’s Biologics License Application (BLA) for the treatment is currently under review by the U.S. Food and Drug Administration (FDA), with a decision expected by Aug. 22, 2026.The U.S. Food and Drug Administration resumed its review of Deramiocel in March after previously issuing a Complete Response Letter in July 2025, indicating the therapy needed additional data for approval. Capricor resubmitted its application with updated Phase 3 HOPE-3 results, which showed a 54% slower decline in upper-limb function and a 91% reduction in cardiac disease progression compared to placebo.Further supporting the findings, cardiac MRI data showed a significant reduction in heart scarring in patients treated with Deramiocel after 12 months. The therapy is designed to reduce inflammation linked to muscle damage in DMD.<h2>Treatment Highlights Patients’ Ability To Feed Themselves</h2>The firm’s management highlighted that video-based assessments of everyday tasks also showed that Deramiocel helped slow disease progression, especially in patients’ ability to feed themselves.“No therapeutic has ever delivered a statistically and clinically meaningful difference in the upper limb functional primary endpoint of Performance of the Upper Limb (PUL v2.0),” said Aravindhan Veerapandiyan, Associate Professor and Director of the Comprehensive Neuromuscular Program at Arkansas Children's Hospital.“These findings were further supported by an alternative measure of upper limb function, specifically video recordings of tasks performed at home, which showed meaningful slowing of disease progression in the ability to self-feed, a function central to patient independence.”Meanwhile, retail sentiment on Stocktwits remained ‘bullish’ over the past 24 hours, amid ‘high’ message volumes.<h2>Hemmati’s Potential FDA Appointment Sparks Retail Buzz</h2>A former Capricor executive is being considered for a key leadership role at the U.S. Food and Drug Administration, according to a Bloomberg <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-04-13/eye-doctor-considered-for-fda-vaccine-post-is-a-fox-news-regular">report</a> last week.Houman Hemmati is among the candidates being interviewed by FDA Commissioner Marty Makary to lead the Center for Biologics Evaluation and Research (CBER), the division responsible for reviewing vaccines and advanced gene and cell therapies, including treatments for rare diseases like Duchenne muscular dystrophy.However, no final decision has been made yet, and the agency is still reviewing potential candidates.One user expects the stock to pop on the confirmation of the news.<stembedurl>https://stocktwits.com/haha1978/message/650933730</stembedurl>The leadership vacancy at the CBER follows the departure of Vinay Prasad, whose tenure drew criticism from parts of the biotech industry over regulatory decisions on rare-disease treatments.The stock has gained more than 17% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CAPR Stock Draws Investor Attention After AAN Presentation For DMD Therapy

The biotech firm presented data from its Phase 3 HOPE-3 trial of Deramiocel for Duchenne Muscular Dystrophy at the American Academy of Neurology 2026 Annual Meeting in Chicago.

Short Interest in Capricor Therapeutics, Inc. (NASDAQ:CAPR) Increases By 34.6%

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) was the target of a large growth in short interest in March. As of March 31st, there was short interest totaling 9,878,573 shares, a growth...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) have received a consensus rating of "Moderate Buy" from the ten brokerages that are currently covering the firm, MarketBeat...

<ul class="summary-bullets"><li>Hemmati served as Capricor’s vice president of medical and clinical development for new therapies between 2015 and 2017.</li><li>Capricor is awaiting an FDA decision on its DMD therapy, Deramiocel, expected by Aug. 22.</li><li>The FDA resumed review last month after issuing a Complete Response Letter in July 2025, requesting additional clinical data.</li></ul>Shares of Capricor Therapeutics (CAPR) jumped 1% in premarket trading on Tuesday after reports said a former company executive is being considered to lead the FDA’s top gene therapy division just months before a key approval decision on its Duchenne muscular dystrophy (DMD) treatment.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> jumped 11% on Monday to end at $34.54, logging its best session in nearly two months.<h2 class="st-heading-2">Former Capricor Executive Emerges As FDA Biologics Chief Candidate</h2>Houman Hemmati, who served as vice president of medical and clinical development for new therapies at Capricor between 2015 and 2017, is among the candidates being interviewed by FDA Commissioner Marty Makary to head the Center for Biologics Evaluation and Research, or CBER, Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-04-13/eye-doctor-considered-for-fda-vaccine-post-is-a-fox-news-regular">reported</a>.The division oversees approvals of vaccines and advanced gene and cell therapies, including treatments for rare diseases such as DMD. However, HHS spokesperson Andrew Nixon reportedly said no selection has been finalized and that the agency is still evaluating candidates.<h2 class="st-heading-2">CAPR Awaits Key FDA Ruling On DMD Therapy</h2>The development comes as Capricor awaits an FDA decision on Deramiocel, its investigational therapy for DMD, a rare genetic condition that causes progressive muscle weakness in children, expected by Aug. 22.The FDA resumed review of Deramiocel last month after issuing a Complete Response Letter (CRL) in July 2025, which indicated earlier that the agency could not approve the drug in its current form and typically requests additional data. Capricor’s resubmission included Phase 3 Hope-3 trial results showing 54% slower deterioration in upper-limb function and 91% slowing of cardiac disease progression, both statistically significant compared with placebo.Deramiocel consists of donor-derived cardiac cells, which reduces inflammation linked to muscle degeneration in DMD.<h2 class="st-heading-2">Prasad Exit Seen As Positive For Biotech Approvals</h2>The CBER leadership opening follows the departure this month of outgoing director Vinay Prasad, whose tenure drew criticism from the biotech industry over regulatory decisions affecting rare-disease therapies.Prasad’s exit news lifted several biotech stocks last month, with BMO Capital Markets calling the change “a sigh of relief” for the sector and saying it could improve approval prospects for multiple companies developing advanced therapies.During his tenure, Prasad was involved in disputes with companies, including Sarepta Therapeutics, over gene-therapy reviews and disagreements with UniQure and Regenxbio. He also briefly stepped away from the agency last year amid political criticism over regulatory decisions before returning weeks later with Makary’s support.<h2 class="st-heading-2">How Do Retail Traders Feel About CAPR?</h2>On Stocktwits, retail sentiment for CAPR jumped to ‘bullish’ from ‘bearish’ levels over the past day amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/capr_ss_png_26c2d1b5ac.webp" alt="capr ss.png" width="963" height="149"><figcaption>CAPR sentiment and message volume as of April 14 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/graywolf/message/650157552">said</a>, “$45-50 is my guess if the appointment is confirmed. 75+ upon approval, and $100+ with sale numbers,” referring to the prospects of Hemmati leading the CBER.<stembedurl>https://stocktwits.com/graywolf/message/650157552</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/WBinthehouse/message/650152118">said</a>, “if Dr Hemmati gets appointed as CBER chief, Vinay Prasad is gonna want credit for CAPRs approval. Will beat David to the punch. Guaranteed! Lol”<stembedurl>https://stocktwits.com/WBinthehouse/message/650152118</stembedurl>CAPR stock has jumped over 270% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-killers-musk-taunts-rivals-after-q1-us-deliveries-top-ev-market/cZJpx1BRIHE">'What Happened To All The Tesla Killers?' Elon Musk Taunts Rivals As Q1 US Deliveries Beat Every Other EV Maker Combined</a>

CAPR Stock Gains Steam: Former Capricor Exec Could Become FDA’s Top Gene Therapy Regulator Ahead Of High-Stakes DMD Decision

Outgoing CBER director Vinay Prasad will depart this month, boosting approval prospects for several rare-disease therapies.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

CAPR
Capricor Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Poll

CAPRCapricor Therapeutics Inc